metabolic health crisis

I am delighted to reconnect with Dr. Anurag Singh today, the Chief Medical Officer at Timeline Nutrition. He joined me once before on Episode 268.
I invited Dr. Singh back to discuss the latest research on GLP-1 agonists like Wegovy, Semaglutide, and Ozempic, which are gaining significant traction with projected sales exceeding $100 billion by 2030, potentially affecting 9% of the US population.
In our conversation, we explore the contributors to our metabolic health crisis by looking at the research surrounding GLP-1 agonists, the physiology of GLP-1 peptides, and the influencing elements Dr. Singh refers to as the trifecta. We dive into the loss of muscle mass and strength, sarcopenia, and frailty associated with these drugs, and Dr. Singh shares his concerns about their impact on bone health, the gut microbiome, and their use in younger patients. We also get into lifestyle measures, mitochondrial health, hallmarks of aging, Akkermansia, and the importance of advocacy and patient empowerment.
Today’s compelling and invaluable discussion with Dr. Anurag Singh highlights crucial insights into GLP-1 agonists and their broader health implications. I know it will provide significant value for our listeners.